Letter to the Editor: In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy

J Neuromuscul Dis. 2023;10(6):1151-1153. doi: 10.3233/JND-239004.
No abstract available

Publication types

  • Letter

MeSH terms

  • Clinical Trials, Phase II as Topic
  • Humans
  • Male
  • Muscular Dystrophy, Duchenne*
  • Oligonucleotides

Substances

  • Oligonucleotides
  • viltolarsen